Literature DB >> 17687618

Effects of surgery on peripheral N-terminal propeptide of type III procollagen in patients with Crohn's disease.

Matilde De Simone1, Michele M Ciulla, Ugo Cioffi, Luca Poggi, Barbara Oreggia, Roberta Paliotti, Fiorenzo Botti, Alberto Carrara, Fiorenza Agosti, Alessandro Sartorio, Ettore Contessini-Avesani.   

Abstract

AIM: This study investigates the effects of surgery on collagen turnover in patients affected by Crohn's disease (CD).
METHODS: Fifteen patients affected by active CD, assessed according to the Crohn's disease activity index, and confirmed by histology, with different pharmacological treatments, were enrolled in the study. N-Terminal propeptide of type III collagen was assessed on peripheral blood before and 6 months after surgery, as an index of collagen turnover. A control group of 15 healthy age- and sex-matched subjects was also studied.
RESULTS: In CD patients peripheral N-terminal propeptide of type III collagen serum levels were significantly higher than in controls before surgery (5.0 +/- 1.8 vs 2.7 +/- 0.7 microg/l, respectively; p = 0.0001). Six months after these values were significantly reduced (from 5.0 +/- 1.8 to 3.1 +/- 0.8 microg/l; p = 0.003). Independently on the pretreatment regimen and the duration of the disease, an improvement in the patients' symptoms was observed.
CONCLUSIONS: The surgical resection of the affected intestinal segment in CD patients seems to be able to break down the collagen synthesis processes. Peripheral N-terminal propeptide of type III collagen could be seen as an additive marker to clinical and endoscopic observations after surgery.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17687618     DOI: 10.1007/s11605-007-0233-9

Source DB:  PubMed          Journal:  J Gastrointest Surg        ISSN: 1091-255X            Impact factor:   3.452


  32 in total

1.  Collagen metabolites in the peripheral and splanchnic circulation of patients with Crohn disease.

Authors:  J Kjeldsen; M Rasmussen; O B Schaffalitzky de Muckadell; O Kronborg; P Junker
Journal:  Scand J Gastroenterol       Date:  2001-11       Impact factor: 2.423

Review 2.  Inflammatory bowel disease and environmental influences.

Authors:  Aruna Krishnan; Joshua R Korzenik
Journal:  Gastroenterol Clin North Am       Date:  2002-03       Impact factor: 3.806

3.  Diagnostic markers of inflammatory bowel disease.

Authors:  M C Dubinsky; E G Seidman
Journal:  Curr Opin Gastroenterol       Date:  2000-07       Impact factor: 3.287

4.  European evidence based consensus on the diagnosis and management of Crohn's disease: special situations.

Authors:  R Caprilli; M A Gassull; J C Escher; G Moser; P Munkholm; A Forbes; D W Hommes; H Lochs; E Angelucci; A Cocco; B Vucelic; H Hildebrand; S Kolacek; L Riis; M Lukas; R de Franchis; M Hamilton; G Jantschek; P Michetti; C O'Morain; M M Anwar; J L Freitas; I A Mouzas; F Baert; R Mitchell; C J Hawkey
Journal:  Gut       Date:  2006-03       Impact factor: 23.059

5.  European evidence based consensus on the diagnosis and management of Crohn's disease: definitions and diagnosis.

Authors:  E F Stange; S P L Travis; S Vermeire; C Beglinger; L Kupcinkas; K Geboes; A Barakauskiene; V Villanacci; A Von Herbay; B F Warren; C Gasche; H Tilg; Stefan W Schreiber; J Schölmerich; W Reinisch
Journal:  Gut       Date:  2006-03       Impact factor: 23.059

6.  Increased collagen type III synthesis by fibroblasts isolated from strictures of patients with Crohn's disease.

Authors:  A Stallmach; D Schuppan; H H Riese; H Matthes; E O Riecken
Journal:  Gastroenterology       Date:  1992-06       Impact factor: 22.682

7.  Sequential connective matrix changes in experimental acute pancreatitis. An immunohistochemical and biochemical assessment in the rat.

Authors:  L Uscanga; R H Kennedy; R Choux; M Druguet; J A Grimaud; H Sarles
Journal:  Int J Pancreatol       Date:  1987-02

Review 8.  Inflammatory bowel disease.

Authors:  R K Chutkan
Journal:  Prim Care       Date:  2001-09       Impact factor: 2.907

Review 9.  What are the major arguments in favour of the genetic susceptibility for inflammatory bowel disease?

Authors:  Cyrus P Tamboli; Antoine Cortot; Jean-Frédéric Colombel
Journal:  Eur J Gastroenterol Hepatol       Date:  2003-06       Impact factor: 2.566

10.  Seromarkers of collagen I and III metabolism in active Crohn's disease. Relation to disease activity and response to therapy.

Authors:  J Kjeldsen; O B Schaffalitzky de Muckadell; P Junker
Journal:  Gut       Date:  1995-12       Impact factor: 23.059

View more
  3 in total

1.  Association Between Plasma Level of Collagen Type III Alpha 1 Chain and Development of Strictures in Pediatric Patients With Crohn's Disease.

Authors:  Cortney R Ballengee; Ryan W Stidham; Chunyan Liu; Mi-Ok Kim; Jarod Prince; Kajari Mondal; Robert Baldassano; Marla Dubinsky; James Markowitz; Neal Leleiko; Jeffrey Hyams; Lee Denson; Subra Kugathasan
Journal:  Clin Gastroenterol Hepatol       Date:  2018-09-10       Impact factor: 11.382

Review 2.  Biomarkers of intestinal fibrosis - one step towards clinical trials for stricturing inflammatory bowel disease.

Authors:  Paolo Giuffrida; Massimo Pinzani; Gino R Corazza; Antonio Di Sabatino
Journal:  United European Gastroenterol J       Date:  2016-03-21       Impact factor: 4.623

3.  Misbalance in type III collagen formation/degradation as a novel serological biomarker for penetrating (Montreal B3) Crohn's disease.

Authors:  W T van Haaften; J H Mortensen; M A Karsdal; A C Bay-Jensen; G Dijkstra; P Olinga
Journal:  Aliment Pharmacol Ther       Date:  2017-05-08       Impact factor: 8.171

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.